一位患有胃肠黏膜相关淋巴组织淋巴瘤（MALT）多年的75岁妇女的案例

病史:

首次确诊:2005年5月      原发病部位: MALT 淋巴瘤

首次复发: 2012年11月     复发部位: 左肺上叶

治疗经历:

手术: 无      化疗: 7个周期的CHOP 方案        放疗: 是, 30Gy (胃)

靶向药: 利妥昔单抗        其他免疫治疗: 无     其他: 萨力多胺

临床试验编号: NCT02247609 ;  入组治疗日期: 2017年9月16日

方案:

Flu-Cy淋巴结清扫后进行4SCAR（CD19，PSMA）

CRS 等级: 1 ; 其他反应: 无

疗效判断: PR     生活质量: 提高

患者的疾病缓解期: 1年10个月

目前状况: 伴病存活

CART治疗前后的疾病影像学图像

References：

1）Chang LJ, Dong LJ, Zhu J. et al. (2015) 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass. Blood 126 (23), 264.

2）Jing HM, Chang LJ, Chen MY, Bao F, Wang J, Wang WM, Liu YY, Kuo HH, Liu YC, Dong LJ. (2015) Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy. Blood 126 (23), 5130.

3）L-J Chang, Lujia D, Liu Y-C, Tsao S-T, Li Y-C, Liu L, Gao Z, Tan X, Lu D-P, Zhang J-P, Wang J-B, Ying Y-M, Zhang L-P, Zheng H, Wang K, Zheng X-L, Wang H-X, Lai X, and Li D (2016) Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study. Blood 128 (22), 587.

4） Hao L, Li T, Chang L-J and Chen X. (2017) Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T cells: a systematic review of efficacy and safety. Curr Med Chem.

5）Chang, L.-J., Li, Y. Tu, S. et al. Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas. (2018) Blood 132:225.